Drug Candidate Marketplace
Drug Candidate Marketplace lists the information of drug candidates, therapeutic targets and drug discovery technologies. Visitors can use search functions based on the interests and needs and download the list. If you have a drug candidates, therapeutic targets and drug discovery technologies that you are interested in and would like to gain more information, please contact us by clicking the inquiry button. Additional information will be provided to you.
|Date||Candidate||Mechanism of action||Indication||Route||Modality||Development stage||Note|
|08/21/19||GEM102||Cyclodextrin derivative||Cancer||i.v.||Small molecule
||Preclinical||Modified Methyl-b-Cyclodextrin (CyD).
Displayed potent antitumor activity in vitro, compared to M-β-CyD.
Drastically inhibited tumor growth after a single intravenous injection to tumor-bearing mice, compared to doxorubicin and M-β-CyD, without any significant change in blood chemistry values.
|08/16/19||GEM101||Positive allosteric modulator of GABA-A receptor||Depression and PTSD||Intra-nasal||Peptide
||Preclinical||Exhibited robust mixed anxiolytic and antidepressant activity in vivo animal models. Increased neurogenesis 1 week after single injection.
No decrease in locomotor activity, no sedation.
|08/16/19||GEM100||mGluR5 negative allosteric modulator||Depression and movement disorder||Intra-nasal||Peptide
||Preclinical||mGLuR5 leader peptide was discovered and in vivo efficacy confirmed.
GEM100 specifically increases locomotor activity in rats, with no effects on behavior.
||Preclinical||TrkB peptide modulator discovery was launched.||Contact|
|08/13/19||GEM098||GnRH receptor antagonist||Endometriosis and Uterine fibroids||Oral||Small molecule
||Phase 1||In Phase Ib, GEM098 showed dose-dependent suppression of LH, FSH and E2. The suppressive effects on E2 lasted up to 24 hrs and were more excellent when compared with the published phase 1 data of Elagolix in healthy premenopausal women. No serious adverse events were seen and well tolerated up to 320 mg QD.||Contact|
|08/13/19||GEM097||Factor VIIa derivative||Bypassing therapy in hemophilia with inhibitors||i.v.||Protein
||IND ready||GEM097 is rFVIIa fused to transferrin and has longer half-lives than rFVIIa in rats and monkeys. A cleavable linker between rFVIIa and trasferrin of GEM097 allows minimal reducuction of FVIIa activity due to fusion. Preclinical (GLP) toxicity studies did not show any toxic evidence in rats or monkeys.||Contact|
|07/31/19||GEM096||Progesterone receptor agonist||Recurrent preterm birth||Oral||Small molecule
||Phase 2 completed||Potentially the first oral hydroxyprogesterone caproate product candidate indicated for the prevention of recurrent preterm birth and has been granted orphan drug designation by the FDA. An end of Phase 2 meeting was completed with the FDA.
|07/31/19||GEM095||Androgen receptor agonist||NASH, Cirrhosis||Oral||Small molecule
||Phase 1||An oral prodrug of bioidentical testosterone that is being developed as a treatment of cirrhotic non-alcoholic steatohepatitis (NASH).||Contact|
|07/31/19||GEM094||Androgen receptor agonist||NASH, Pre-Cirrhosis||Oral||Small molecule
||Phase 2 ongoing||An oral prodrug of bioidentical testosterone that is being developed as a treatment of non-alcoholic steatohepatitis (NASH) and is being studied in the LifT Phase 2 clinical study in biopsy confirmed NASH subjects.||Contact|
|07/31/19||GEM093||Androgen receptor agonist||Hypogonadism||Refer to Note||Small molecule
||Phase 2 completed||Route: Oral (QD)
A novel next generation oral prodrug of testosterone with potential for once-daily oral dosing that has completed Phase 2 testing.